




(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2003/09/30
(87) Date publication PCT/PCT Publication Date: 2004/04/08
(85) Entrée phase nationale/National Entry: 2005/03/21
(86) N° demande PCT/PCT Application No.: DK 2003/000645
(87) N° publication PCT/PCT Publication No.: 2004/029046
(30) Priorité/Priority: 2002/09/30 (PA 2002 01450) DK

(51) Cl.Int.⁷/Int.Cl.⁷ C07D 409/12, A61K 31/445,
A61K 31/381, A61P 35/00, A61P 19/00, C07D 295/08,
C07D 333/56
(71) Demandeur/Applicant:
A/S GEA FARMACEUTISK FABRIK, DK
(72) Inventeurs/Inventors:
KARUP, GUNNAR LEO, DK;
PEDERSEN, SOREN BOLLS, DK
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : NOUVEAUX SELS D'ADDITION ACIDES DE RALOXIFENE ET/OU SOLVATES DE CEUX-CI, PROCEDE AMELIORE PERMETTANT LA PURIFICATION DE CES SELS D'ADDITION ACIDES ET/OU DE CES SOLVATES, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
(54) Title: NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE



(57) Abrégé/Abstract:

Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation. A new method for preparation of raloxifene lactate is also disclosed.